SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

City Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value

(Title of Class of Securities)

(CUSIP Number)

Mark McDonnell
ARCH Venture Management, LLC, 8755 W. Higgins Road, Suite 1025
Chicago, IL, 60631
(773) 380 6600

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

10/19/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

1	Name of reporting person ARCH Venture Fund XII, L.P.
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☐ (b)
3	SEC use only

4	Source of funds (See Instructions)	
	WC	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)	
	☐	
6	Citizenship or place of organization	
	DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power
		0.00
	8	Shared Voting Power
		13,692,507.00
	9	Sole Dispositive Power
		0.00
	10	Shared Dispositive Power
		13,692,507.00
11	Aggregate amount beneficially owned by each reporting person	
	13,692,507.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)	
	☐	
13	Percent of class represented by amount in Row (11)	
	25.6 %	
14	Type of Reporting Person (See Instructions)	
	PN	

SCHEDULE 13D

CUSIP No.

1	Name of reporting person	
	ARCH Venture Partners XII, L.P.	
2	Check the appropriate box if a member of a Group (See Instructions)	
	☐ (a) ☐ (b)	
3	SEC use only	
4	Source of funds (See Instructions)	
	WC	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)	
	☐	
6	Citizenship or place of organization	
	DELAWARE	
Number of Shares Beneficially Owned by	7	Sole Voting Power
		0.00
	8	Shared Voting Power

Each Reporting Person With:		13,692,507.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 13,692,507.00
11		Aggregate amount beneficially owned by each reporting person 13,692,507.00
12		Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐
13		Percent of class represented by amount in Row (11) 25.6 %
14		Type of Reporting Person (See Instructions) PN

SCHEDULE 13D

CUSIP No.

1		Name of reporting person ARCH Venture Partners XII, LLC
2		Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☐ (b)
3		SEC use only
4		Source of funds (See Instructions) AF
5		Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6		Citizenship or place of organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00
	8	Shared Voting Power 13,692,507.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 13,692,507.00
11		Aggregate amount beneficially owned by each reporting person 13,692,507.00
12		Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

☐

Percent of class represented by amount in Row (11)

13

25.6 %

Type of Reporting Person (See Instructions)

14

OO

SCHEDULE 13D

CUSIP No.

Name of reporting person

1

Robert Nelsen

Check the appropriate box if a member of a Group (See Instructions)

2

☐ (a)
☐ (b)

3 SEC use only

Source of funds (See Instructions)

4

AF

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

☐

Citizenship or place of organization

6

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00
	8	Shared Voting Power 13,692,507.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 13,692,507.00

Aggregate amount beneficially owned by each reporting person

11

13,692,507.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

☐

Percent of class represented by amount in Row (11)

13

25.6 %

Type of Reporting Person (See Instructions)

14

IN

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Keith Crandell	
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☐ (b)	
3	SEC use only	
4	Source of funds (See Instructions) AF	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐	
6	Citizenship or place of organization UNITED STATES	
Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00
	8	Shared Voting Power 13,692,507.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 13,692,507.00
11	Aggregate amount beneficially owned by each reporting person 13,692,507.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐	
13	Percent of class represented by amount in Row (11) 25.6 %	
14	Type of Reporting Person (See Instructions) IN	

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Kristina Burow
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☐ (b)
3	SEC use only
4	Source of funds (See Instructions)

AF

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

☐

Citizenship or place of organization

6

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

Sole Voting Power

7

0.00

Shared Voting Power

8

13,692,507.00

Sole Dispositive Power

9

0.00

Shared Dispositive Power

10

13,692,507.00

Aggregate amount beneficially owned by each reporting person

11

13,692,507.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

☐

Percent of class represented by amount in Row (11)

13

25.6 %

Type of Reporting Person (See Instructions)

14

IN

SCHEDULE 13D

CUSIP No.

Name of reporting person

1

Steven Gillis

Check the appropriate box if a member of a Group (See Instructions)

2

☐ (a)
☐ (b)

3 SEC use only

Source of funds (See Instructions)

4

AF

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

☐

Citizenship or place of organization

6

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting

Sole Voting Power

7

0.00

Shared Voting Power

8

13,692,507.00

Person With:	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 13,692,507.00
11		Aggregate amount beneficially owned by each reporting person 13,692,507.00
12		Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐
13		Percent of class represented by amount in Row (11) 25.6 %
14		Type of Reporting Person (See Instructions) IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, $0.0001 par value
(b)	Name of Issuer: City Therapeutics, Inc.
(c)	Address of Issuer's Principal Executive Offices: 399 Binney Street, Cambridge, MASSACHUSETTS , 02142.
Item 1 Comment:	This statement relates to the Common Stock, $0.0001 par value (the "Common Stock"), of City Therapeutics, Inc. (the "Issuer") having its principal executive office at 399 Binney Street, Cambridge, MA 02142.
Item 2.	Identity and Background
(a)	This statement is being filed by (1) ARCH Venture Fund XII, L.P. ("AVF XII"), (2) ARCH Venture Partners XII, L.P. ("AVP XII LP") which is the sole general partner of AVF XII, (3) ARCH Venture Partners XII, LLC ("AVP XII LLC") which is the sole general partner of AVP XII LP, (4) Keith Crandell ("Crandell"), (5) Robert Nelsen ("Nelsen"), (6) Kristina Burow ("Burow"), and (7) Steven Gillis ("Gillis"). Nelsen, Crandell, Burow, and Gillis are referred to collectively as the "AVP XII Investment Committee Members". Each of the individuals and entities above shall be referred to herein as a "Reporting Person" and collectively as the "Reporting Persons."
(b)	The business address of each of the Reporting Persons is 8755 West Higgins Road, Suite 1025, Chicago, IL, 60631.
(c)	The principal business of AVP XII LP is to act as the general partner of AVF XII and the principal business of AVP XII LLC is to act as the general partner of AVP XII LP. AVP XII Investment Committee Members act as investment committee members of AVP XII LLC, and as managing directors or investment committee members of a number of affiliated partnerships with similar businesses.
(d)	During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding.
(e)	During the five years prior to the date hereof, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.
(f)	AVF XII and AVP XII LP are limited partnerships organized under the laws of the State of Delaware. AVP XII LLC is a limited liability company organized under the laws of the State of Delaware. Each AVP XII Committee Member is a US citizen.
Item 3.	Source and Amount of Funds or Other Consideration
	On May 20, 2026, AVF XII purchased 2,027,006 shares of Series B Preferred Stock of the Issuer at a purchase price of $13.3201 per share. The number of shares reflects a 1.0983 for 1 stock split effected immediately prior to the closing of the initial public offering of the Issuer (the "IPO"). Each share of Series B Preferred Stock automatically converted into one share of the Issuer's Common Stock at the closing of the IPO. On October 19, 2026, AVF XII purchased 170,000 shares of Common Stock at a purchase price of $18.00 per share from the underwriters of the IPO.

The source of funds for each of the purchases described in this Item 3 was the working capital of AVF XII. No part of the purchase price paid by AVF XII was represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring, holding, trading or voting the shares of Common Stock described above. The total amount paid by for securities purchased in the above-listed transactions is as follows: AVF XII: $30,059,985.76

Item 4. Purpose of Transaction

AVF XII and the other Reporting Persons acquired the Common Stock for investment purposes. Depending on market conditions, the continuing evaluation of the business and prospects of the Issuer and other factors, AVF XII and other Reporting Persons may dispose of or acquire additional shares of Common Stock of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D.

Item 5. Interest in Securities of the Issuer

(a) AVF XII is the record owner of 13,692,507 shares of Common Stock ("AVF XII Record Shares"). AVP XII LP, as the sole general partner of AVF XII LP, may be deemed to beneficially own the AVF XII Record Shares. AVP XII LLC, as the sole general partner of AVP XII LP, may be deemed to beneficially own the AVF XII Record Shares. By virtue of their relationship as affiliated entities who have overlapping general partners and investment committee members, each of the AVP XII Investment Committee Members and direct and indirect general partners of AVF XII may be deemed to share the power to direct the AVF XII Record Shares. Each Reporting Person disclaims beneficial ownership of the Record Shares except for the shares, if any, held of record by such Reporting Person. The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person's cover sheet. Such percentage was calculated based on the 53,387,834 shares outstanding following the IPO, including full exercise of the underwriters' option, as reported by the Issuer in its Prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on October 16, 2026.

(b) Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets. (ii) shared power to vote or to direct the vote: See line 8 of cover sheets. (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets. (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets.

(c) Except as set forth above, none of the Reporting Persons has effected any transaction in the Common Stock during the last 60 days.

(d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, shares beneficially owned by any of the Reporting Persons.

(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

AVF XII is party to that certain Amended and Restated Investors' Rights Agreement, dated May 20, 2026 (the "Investor Rights Agreement"). Pursuant to the Investor Rights Agreement, the Issuer has granted to AVF XII demand, piggyback and shelf registration rights with respect to shares of Common Stock held by AVF XII. Such registration rights will terminate upon the earlier of (i) the closing of a "Deemed Liquidation Event," as such term is defined in our certificate of incorporation (as currently in effect), (ii) the fifth anniversary of the completion of this offering and (iii) such time after consummation of this offering as SEC Rule 144 or another similar exemption under the Securities Act is available for the sale of all of the securities subject to such registration rights without limitation during a three-month period without registration. Effective as of the closing of the IPO, the covenants relating to delivery of financial statements, inspection rights, and observer rights set forth in Section 3 and the rights of first offer were terminated. The foregoing description of the Investor Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement, which is filed as Exhibit 2 to this Schedule 13D and is incorporated herein by reference. AVF XII has entered into a lock-up agreement with the underwriters of the IPO (the "Lock-Up Agreement") pursuant to which AVF XII has agreed, subject to certain exceptions, not to offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise dispose of, directly or indirectly, or enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock for a period of 180 days after October 15, 2026, except with the prior written consent of Goldman Sachs & Co. LLC and Jefferies LLC, subject to certain exceptions. The foregoing description of the Lock-Up Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement, the form of which is filed as Exhibit 3 to this Schedule 13D and is incorporated herein by reference.

Item 7. Material to be Filed as Exhibits.

Exhibit 1- Agreement of Joint Filing Exhibit 2- Amended and Restated Investors' Rights Agreement, dated May 20, 2026, as amended, by and among the Issuer and certain of its stockholders (incorporated by reference to Exhibit 4.2 to the Issuer's Registration Statement on Form S-1/A, filed with the Securities and Exchange Commission on October 9, 2026). Exhibit 3- Form of Lock-Up Agreement (incorporated by reference to Annex II to the Form of Underwriting Agreement filed as Exhibit 1.1 to the Issuer's Registration Statement on Form S-1/A, filed with the Securities and Exchange Commission on October 9, 2026).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ARCH Venture Fund XII, L.P.

Signature: ARCH Venture Partners XII, L.P.
Name/Title: its General Partner
Date: 10/26/2026

Signature: ARCH Venture Partners XII, LLC
Name/Title: its General Partner
Date: 10/26/2026

Signature: /s/ Mark McDonnell*
Name/Title: Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date: 10/26/2026

ARCH Venture Partners XII, L.P.

Signature: ARCH Venture Partners XII, LLC
Name/Title: its General Partner
Date: 10/26/2026

Signature: /s/ Mark McDonnell*
Name/Title: Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date: 10/26/2026

ARCH Venture Partners XII, LLC

Signature: /s/ Mark McDonnell*
Name/Title: Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date: 10/26/2026

Robert Nelsen

Signature: /s/ Mark McDonnell*
Name/Title: Mark McDonnell, as Attorney-in-Fact for Robert Nelsen
Date: 10/26/2026

Keith Crandell

Signature: /s/ Mark McDonnell*
Name/Title: Mark McDonnell, as Attorney-in-Fact for Keith Crandell
Date: 10/26/2026

Kristina Burow

Signature: /s/ Mark McDonnell*
Name/Title: Mark McDonnell, as Attorney-in-Fact for Kristina Burow
Date: 10/26/2026

Steven Gillis

Signature: /s/ Mark McDonnell*
Name/Title: Mark McDonnell, as Attorney-in-Fact for Steven Gillis
Date: 10/26/2026

Comments accompanying signature: *This Schedule 13D was executed by Mark McDonnell pursuant to a Power of Attorney filed as Exhibit 24.2 to the Form 3 relating to the beneficial ownership of shares of Neumora Therapeutics, Inc. by the Reporting Persons filed with the Securities Exchange Commission on September 14, 2023 and incorporated herein in its entirety by reference.

Exhibit 1

AGREEMENT

Pursuant to Rule 13d-1-(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of City Therapeutics, Inc.

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.

Dated: October 26, 2026

ARCH VENTURE FUND XII, L.P.

By: ARCH Venture Partners XII, L.P.
its General Partner

By: ARCH Venture Partners XII, LLC
its General Partner

By: *
Keith Crandell
Managing Director

ARCH VENTURE PARTNERS XII, L.P.

By: ARCH Venture Partners XII, LLC
its General Partner

By: *
Keith Crandell
Managing Director

ARCH VENTURE PARTNERS XII, LLC

By: *
Keith Crandell
Managing Director

*
Keith Crandell

*
Robert Nelsen

*
Kristina Burow

*
Steven Gillis

* By: /s/ Mark McDonnell
Mark McDonnell as
Attorney-in-Fact

* This Agreement of Joint Filing was executed by Mark McDonnell pursuant to a Power of Attorney filed as Exhibit 24 to the Form 3 relating to the beneficial ownership of shares of Neumora Therapeutics, Inc. by the Reporting Persons filed with the Securities Exchange Commission on September 14, 2023 and incorporated herein in its entirety by reference.